NCI's NCORP 2027 Renewal Cycle Just Opened — $147.5 Million Across Three RFAs, Webinars This Week, and an August 18 Deadline That Locks In Six Years of Community Oncology Trial Infrastructure

The National Cancer Institute's Community Oncology Research Program is the federal government's primary mechanism for delivering cancer clinical trials in community settings — the hospitals, oncology practices, and integrated care systems where roughly 80% of U.S. cancer patients receive care. On May 21, 2026, NCI posted the three competitive renewals that will set the program's structure for the FY 2027 award cycle and a six-year run beyond it: RFA-CA-27-006 for Research Bases, RFA-CA-27-007 for Community Sites, and RFA-CA-27-008 for Academic Community Sites. Combined FY 2027 commitments total $147.5 million across approximately 57 awards. Pre-application webinars run June 16, 17, and 18 this week. Applications are due August 18, 2026 at 5:00 PM local time.

These are the renewals of the awards made under RFA-CA-21-014, RFA-CA-21-015, and RFA-CA-21-016 — the 2021 cycle that established the current NCORP network. Every existing NCORP grantee must compete. There is no non-competing renewal pathway. For institutions whose oncology research portfolios are anchored in NCORP — and there are many — this RFA cycle is existential.

What NCORP Does, and Why the Structure Matters

NCORP exists because the clinical-trials infrastructure that NCI built around academic medical centers in the 1970s and 1980s does not reach the patients who need it most. Roughly 5% of adult cancer patients in the U.S. enroll in clinical trials. The figure is lower in rural areas, lower in communities of color, and lower among patients with public insurance. The geographic distribution of trial-capable infrastructure is concentrated in 30-odd academic medical centers that account for a small share of U.S. cancer care. NCORP is the program designed to fix that.

The three-component architecture is deliberate. Research Bases (RFA-CA-27-006) are the protocol-development engines: they design, implement, analyze, and report on multi-institutional cancer prevention, control, screening, supportive care, surveillance, and care-delivery trials. They operate the data infrastructure, the central IRB processes, the quality assurance systems, and the statistical-analysis cores. Research Bases are typically housed at NCI-designated cancer centers, cancer foundations affiliated with NCI Clinical Trials Network (NCTN) groups, or NCTN groups themselves. NCI's FY 2027 commitment for Research Bases is $74.5 million for up to 7 awards, with required six-year project periods.

Community Sites (RFA-CA-27-007) and Academic Community Sites (RFA-CA-27-008) are the enrollment engines. They are healthcare-providing entities — community hospitals, oncology consortia, integrated health systems — that accrue patients onto trials designed and managed by Research Bases. They do not operate the trials themselves. NCI's combined FY 2027 commitment for Community Sites and Academic Community Sites is $73 million for up to 50 awards. The eligibility distinction matters: NCI-Designated Cancer Centers, NCTN Lead Academic Participating Sites, Department of Veterans Affairs hospitals, and Department of Defense military treatment facilities are explicitly ineligible for RFA-CA-27-007. Those institutions have other federal channels for trial participation. Community Sites are intended to reach patients those channels do not.

For prior cycle context, see our coverage of the larger NIH funding architecture in NIH Multiyear Funded Grants: $402 Million in FY26 and Granted News.

The Six-Year Lock-In

Every NCORP award in this cycle has a mandatory six-year project period. This is unusual for NIH and is a load-bearing design choice. Cancer clinical trials are long. A randomized adjuvant therapy trial that opens to accrual in 2027 will not complete primary endpoint follow-up until 2031 or 2032. A care-delivery intervention trial that requires steady-state enrollment for two years before mature data is available has the same timeline. Six years lets a single award fund a complete trial lifecycle without the disruption of a renewal in the middle of accrual.

The flip side is that six years locks in a decision. An institution that wins an award in 2027 is committed to NCORP infrastructure — central IRB, data systems, quality assurance, accrual targets, reporting cadence — until 2033. An institution that does not win is locked out for the same period. This is the longest single commitment NIH makes outside of program project grants and cooperative agreements at the National Center scale.

Accrual Math and Per-Patient Economics

The Community Sites funding model is a per-patient management fee structure layered over infrastructure costs. Sites earn $3,000 to $6,000 per patient accrued, depending on trial type — treatment trials pay more than prevention or screening trials — and site performance tier. Minimum accrual targets are 70 new patients annually for adult-focused sites and 50 new patients annually for pediatric sites, split evenly between treatment trials and cancer control / prevention trials.

That accrual requirement is binding. Sites that fall below threshold lose award status. Sites that consistently exceed threshold can request supplemental funding for additional infrastructure. The per-patient model means the funding scales with actual trial participation rather than being decoupled from output. For community hospitals, the model creates a clean operational picture: you are paid for what you accrue, against a baseline infrastructure budget that supports the staffing required to accrue at all.

The 70-patient minimum is also a meaningful filter. A community oncology practice that sees 800 new cancer patients per year — roughly the threshold for a mid-sized U.S. community oncology program — needs to enroll about 9% of its new patients onto trials to hit the minimum. That is more than double the national average of 4-5%. It requires a trial-screening culture, a research-nurse staffing model, and a referring-physician relationship pattern that does not exist by default. Existing NCORP sites have built that infrastructure. New entrants will need to demonstrate either the capacity or a credible plan to develop it within the first year of the award.

Application Budgets and the "Not Limited" Flag

Both RFAs state that application budgets are not limited but need to reflect the actual needs of the proposed project. This phrasing is common in NIH UG1 cooperative agreement RFAs but means something specific. It does not mean budgets can be arbitrarily large. It means NCI has not set a per-award ceiling, but applications must justify every dollar against a defined scope of work and a defined accrual or operational target.

In practice, Research Base awards under the current cycle range from roughly $8 million to $14 million per year, with the larger awards going to multi-disease, multi-modality groups that operate national protocol portfolios. Community Site awards range from roughly $1 million to $3 million per year, with the larger awards reflecting either pediatric-focused sites or sites with substantial minority/underserved accrual portfolios. Applicants for the new cycle should anchor budgets in actual operational data: real accrual numbers, real staffing patterns, real protocol activation volumes. NCI's review panels see hundreds of these budgets and will identify aspirational numbers immediately.

The Webinar Sequence and What to Get Out of It

Pre-application webinars on June 16, 17, and 18 are not optional in any meaningful sense. NCI uses these sessions to clarify priorities, signal evaluative emphasis, and answer technical questions about the renewal application requirements. Three things in particular are worth listening for.

First, the research priority emphasis. The 2021 cycle prioritized cancer care delivery research, disparities research, and supportive care. The 2027 cycle is expected to layer on AI-enabled clinical trial operations, real-world evidence integration, and decentralized trial methodologies — topics NCI has signaled through recent Notices of Special Interest. Webinar Q&A will sharpen the agency's priorities in ways that will not appear in the formal RFA text.

Second, accrual target methodology. NCI is expected to revise accrual targets to account for the post-pandemic shift in trial participation. Existing sites should listen for any signal about whether 70-patient minimums will be enforced as a hard threshold or as a rolling-average target.

Third, transition arrangements for current grantees. Sites that do not successfully compete will need bridge funding to wind down active trials, transfer enrolled patients, and complete reporting. NCI typically offers transition supplements, but the structure varies cycle to cycle.

Strategic Implications for Different Applicant Types

For existing Research Bases: the seven-award cap is the same number NCI funded in the 2021 cycle. Competition will be intense among the current incumbents, particularly the disease-specific groups that have specialized portfolios (pediatric, GI, GU, supportive care). Differentiation will come from demonstrated leadership in care-delivery research, integration with real-world evidence partnerships, and credible plans for AI/ML-enabled trial operations. Renewal applications should emphasize completed trials with practice-changing results from the 2021-2027 award period.

For existing Community Sites: the 50-site cap is similar to the 2021 cycle, but NCI has signaled interest in expanding Academic Community Sites at the expense of standalone Community Sites. Sites that have evolved from pure-accrual operations to research-active community-academic partnerships will be advantaged. Sites that have not built academic affiliations should evaluate partnerships before the August 18 deadline.

For new entrants: NCI rarely funds new Community Sites in renewal cycles — the operational lift to build NCORP infrastructure from scratch is steep, and incumbent sites have the relationships with Research Bases that drive trial activation. New entrants succeed when they bring meaningful patient populations that current NCORP sites do not reach: rural catchment areas, predominant-minority populations, specific disease populations underrepresented in current trials. The application narrative needs to make the patient-population case before the operational case.

For consortia exploring formation: the application allows for partnerships among multiple community oncology practices that collectively meet the accrual threshold. This is the path for mid-sized practices that cannot meet 70-patient minimums alone. Consortium applications require additional governance and operational complexity but are explicitly allowed.

Interaction with Other 2026 NIH Cycles

The August 18 deadline falls inside a crowded NIH window. NIH RFAs in the cancer space with overlapping deadlines include the Experimental Therapeutics Clinical Trials Network Lead Academic Organizations (RFA-CA-27-016) and the Advanced Development of Informatics Technologies for Cancer Research (RFA-CA-27-020) cycles. Institutions that participate in multiple NCI networks need to coordinate application calendars. The ETCTN and NCORP networks are not interchangeable — different scientific scopes, different review panels, different award mechanisms — but the institutional infrastructure that supports them overlaps substantially.

The proposed OMB Uniform Grants Regulation, which we covered in OMB's Proposed Federal Grants Overhaul, is unlikely to affect this cycle directly — the comment period closes July 13, the proposed effective date is October 1, and the rule does not apply retroactively to active awards. But the political-review provisions of the proposed rule will apply to FY 2028 supplements and amendments. Applicants should structure their proposed work to be defensible on substantive scientific merit grounds rather than on policy-aligned framings that could become liabilities in a future review cycle.

Practical Application Strategy

Read the full RFAs cover to cover. Attend all three webinars or have institutional reviewers split coverage. Identify the named scientific contact for each RFA and request a 30-minute call before mid-July to validate that your application concept fits NCI's evaluation framework. Build the application around demonstrated accrual data, demonstrated trial activation timelines, and demonstrated impact on practice patterns from prior award periods.

For applications going through complex institutional review, August 18 means an early-August internal submission deadline. NIH's eRA Commons system traditionally experiences significant load near major submission deadlines, and a six-year cooperative agreement application with the full required attachments is not a document you want submitting at 4:55 PM. Plan for submission by August 14 to leave buffer.

What to Do on Granted Today

Search Granted for the full NCORP RFA package, related NCI cycle deadlines, and adjacent cooperative agreement opportunities. Browse our cancer research grant database for cohort-recruitment and trial-infrastructure supplements that can layer onto a successful NCORP award. If you are an existing NCORP grantee preparing a renewal, search past awardees for benchmarking your accrual numbers and protocol portfolio against the current grantee pool. The August 18 deadline is sixty-two days away. Webinar week starts tomorrow.